Free through Q3 2026. Founding subscribers lock the founding rate for the life of the subscription.
Everything is free through the end of 2026. Coverage Alpha publishes through Q3 earnings season at no cost. Paid subscriptions open in January 2027, timed to the national formulary template drops. Anyone on the list before then is a founding subscriber.
An individual Pro tier at $349 per month will add the Excel workbooks that sit behind each issue — the WAC tracker, franchise revenue builds, and gross-to-net sensitivity models — for subscribers who want the underlying analysis rather than only the conclusions. It launches alongside paid access in January.
Because research is bought on track record, not promises. Publishing through an entire earnings season gives you an archive to judge before anyone is asked to pay, and gives the publication time to prove it can hold the 48-hour cadence under real conditions.
The founding rate holds for as long as the subscription remains active and uninterrupted. If list pricing rises later — and it likely will as the coverage universe and the workbook library expand — founding subscribers stay at $99.
That is the design intent. Both the individual and founding tiers sit below the threshold at which most organizations require additional approval, and an invoice suitable for expense submission is provided automatically.
Single-company coverage is not offered, deliberately. The value of the brief is comparative. One company's pricing doctrine sets the terms every competitor in that category has to negotiate against, and that read-through is the analysis worth paying for. A brief that covered your company alone would tell you what you already know.
Every issue free through the end of the year. Founding subscribers lock $99/month for the life of the subscription when paid access opens in January 2027.
Independent publication. Not investment advice. Unsubscribe anytime.